ClinicalTrials.gg
Status unknownNCT04325763Updated Mar 31, 2022

A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

A Phase 3 interventional study of TQB2450 and Anlotinib in Stage III Non-small-cell Lung Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 36 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-03-31.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
315
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing benmelstobart in Carcinoma, Non-Small-Cell Lung — 9 open to participants now, 9 under way, 2 of them phase 3. benmelstobart · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
4th of 14
315 · median 154
Started
2020
with 1 other
Phase 3
5 of 14
2 open now
Registered
3rd of 14
by date
Lead sponsor
7 of 14
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 14 studies testing benmelstobart in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by planned enrollment, is one of 2 that started in 2020, is one of 5 in phase 3, and was the 3rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

9 of the 14 studies testing benmelstobart in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About benmelstobart

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing benmelstobart in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, double-dummy,placebo parallel controlled, multi-centre,phase III clinical trial to evaluate the efficacy and safety of TQB2450 with or without anlotinib compared with placebo as consolidation treatment in subjects with locally advanced/unresectable (Stage III) Non-Small Cell Lung Cancer that has not progressed after prior concurrent/sequential chemoradiotherapy.

03

Conditions studied

  • Stage III Non-small-cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-75 years old ; (ECOG) performance status of 0 to 1; ≥ 3 months.
  2. or cytologically confirmed unresectable (Stage III) Non-Small Cell Lung Cancer.
  3. At least has one before radiotherapy.
  4. At least has one type of platinum-containing chemotherapy, Absence of progression after concurrent/sequential chemoradiotherapy.
  5. Adequate laboratory indicators.
  6. No pregnant or breastfeeding women, and a negative pregnancy test.
  7. Understood and signed an form.

Exclusion criteria

Exclusion Criteria:

  1. Squamous cell carcinoma meets following conditions should be excluded:

    1. Cavernous lung cancer.
    2. Has hemoptysis and maximum daily hemoptysis volume ≥ 2.5ml within 1 month before the first administration.
  2. Has received anti-angiogenic drugs or other / PD-L1 / CTLA-4 antibody therapy or other immunotherapy against PD-1 / PD-L1 / CTLA-4.
  3. Severe occurs after administration of other monoclonal antibodies.
  4. Diagnosed and/or treated additional within 5 years with the exception of cured basal cell carcinoma of skin ,carcinoma in situ of prostate,and carcinoma in situ of cervix.
  5. confirmed mixed small cell and non-small cell lung cancer.
  6. EGFR gene mutations.
  7. Has any active disease or history of autoimmune disease.
  8. After the early stage of chemoradiotherapy, the treatment toxicity ≥ grade 2 is not fully alleviated.
  9. Has ≥grade 2 pneumonia.
  10. or systemic or absorbable local hormone therapy is required to achieve the aim of immunosuppression (dose > 10mg/ day prednisone or other therapeutic hormones) and is still used within 2 weeks after the first administration.
  11. Has multiple factors affecting oral medication.
  12. Has active bleeding or a persistent decrease in .
  13. Has any bleeding or bleeding events ≥grade 3 in the first 4 weeks before the first administration.

2.Has received anti-angiogenic drugs or other PD-1 / PD-L1 / CTLA-4 antibody therapy or other immunotherapy against PD-1 / PD-L1 / CTLA-4.

  1. Has unhealed wounds, fractures, active gastric and duodenal ulcers, positive continuous fecal occult blood, ulcerative colitis in the first 4 weeks before the first administration.
  1. Has received NMPA approved anti-tumor drugs or immunomodulatory drugs for systemic treatment within 2 weeks before the first administration.

16.Has a history of a hematological system transplantation or organ transplantation.

  1. Has active diverticulitis、peritoneal abscess, intestinal obstruction. 18. Has any serious and/or uncontrollable disease. 19. According to the judgement of the investigators, there are other factors that may lead to the termination of the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
315 participants (estimated)

Study arms

  • Experimental
    TQB2450+Anlotinib

    TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 8 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

    Drug: TQB2450 · Drug: Anlotinib

  • Experimental
    TQB2450+Anlotinib(blank)

    TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 0 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

    Drug: TQB2450 · Drug: Anlotinib(blank)

  • Placebo comparator
    TQB2450(blank)+Anlotinib(blank)

    TQB2450 0 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 0 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

    Drug: TQB2450(blank) · Drug: Anlotinib(blank)

Interventions

  • TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

  • a multi-target receptor tyrosine kinase inhibitor

  • DrugTQB2450(blank)

    Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day

  • Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) evaluated by Independent Review Committee(IRC)

    PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause, based on IRC.

    Time frame: up to 33 months

Secondary outcomes

  1. PFS evaluated by Investigator

    PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause, based on investigator.

    Time frame: up to 33 months

  2. Overall survival (OS)

    OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.

    Time frame: up to 5 years

  3. Overall response rate (ORR)

    Percentage of participants achieving complete response (CR) and partial response (PR).

    Time frame: up to 33 months

  4. Disease control rate(DCR)

    Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).

    Time frame: up to 33 months

  5. Duration of response(DOR)

    The time when the participants first achieved complete or partial remission to disease progression.

    Time frame: up to 33 months

  6. PFS rate at month 6

    The percentage of PFS at month 6

    Time frame: up to 6 months

  7. PFS rate at month 12

    The percentage of PFS at month 12

    Time frame: up to 12 months

  8. Biomarkers, such as PD-L1 expression, etc.

    Tissue samples were collected during the screening period for pd-l1 analysis. Blood samples were collected for Tumor Mutation Burden (TMB) test before enrollment (within 7 days before medication) and after exit (±3 days).

    Time frame: up to 33 months

  9. Immunogenicity, such as the incidence of ADA

    Degree of the immune response caused by the drug.

    Time frame: on day 1, 42, 105, 189 and 90 days after the last administration.

07

Study locations

6 of 36 sites recruiting
  • Anhui Chest Hospital
    Hefei, Anhui 230000, China
    Not yet recruiting
  • Peking Union Medical College Hospital
    Beijing, Beijing 100730, China
    Not yet recruiting
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing 400000, China
    Recruiting
    • Yue Xie, Master · Contact344899525@qq.com · 023-65079227
    • Yue Xie, Master · Principal investigator
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 400000, China
    Not yet recruiting
    • Yuxi Zhu, Doctor · Contact724513168@qq.com · 023-68811360
    • Yuxi Zhu, Doctor · Principal investigator
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350000, China
    Not yet recruiting
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
    Recruiting
    • Ming Chen, Doctor · Contactchenming@zjcc.org.cn · 020-87343543
    • Ming Chen, Doctor · Principal investigator
  • The First Affiliated Hospital Sun Yat-Sen University
    Guangzhou, Guangdong 510080, China
    Not yet recruiting
    • Yong Bao, Doctor · Contactbaoyong@sysucc.org.cn · 020-86668114
    • Yong Bao, Doctor · Principal investigator
  • Yuebei People's Hospital
    Shaoguan, Guangdong 512025, China
    Not yet recruiting
    • Suming Pan, Master · Contact0751-6913383
    • Suming Pan, Master · Principal investigator
  • Affiliated Hospital of Guangdong Medical University
    Zhangjiang, Guangdong 524000, China
    Not yet recruiting
    • Hualin Chen, Doctor · Contact3549509@qq.com · 0759-2387458
    • Hualin Chen, Doctor · Principal investigator
  • The Fifth Affiliated Hospital Sun Yat-Sen University
    Zhuhai, Guangdong 519000, China
    Recruiting
    • Zhigang Liu, Doctor · Contact85172626@qq.com · 0756-2526192
    • Zhigang Liu, Doctor · Principal investigator
  • Guangxi Medical University Affiliated Tumor Hospital
    Nanning, Guangxi 530200, China
    Not yet recruiting
    • Long Chen, master · Contactclong6@126.com · 0771-5310364
    • Long Chen · Principal investigator
  • The Fourth Hospital of Hebei medical University
    Shijiazhuang, Hebei 050019, China
    Not yet recruiting
    • Jun Wang, Doctor · Contactwangjunzr@163.com · 0311-86095667
    • Jun Wang, Doctor · Principal investigator
  • Anyang Cancer Hospital
    Anyang, Henang 455000, China
    Recruiting
    • Anping Zheng, Master · ContactZhenganping3@aliyun.com · 0372-2232091
    • Anping Zheng, Master · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
    Not yet recruiting
    • Hong Ge, Doctor · Contactgehong666@126.com
    • Hong Ge, Doctor · Principal investigator
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
    Not yet recruiting
    • Desheng Hu, Doctor · Contacthds_005@163.com · 027-87670121
    • Desheng Hu, Doctor · Principal investigator
  • Hunan Cancer Hospital
    Changsha, Hunan 410006, China
    Not yet recruiting
    • hui Wang, Doctor · Contactwanghui710327@163.com · 0731-89762231
    • hui Wang, Doctor · Principal investigator
  • Xiangya Hospital Central South University
    Changsha, Hunan 410008, China
    Not yet recruiting
    • Rongrong Zhou, Doctor · Contact664990095@qq.com · 0731-89753769
    • Rongrong Zhou, Doctor · Principal investigator
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
    Not yet recruiting
    • Peiguo Cao, Doctor · Contactcaopeiguo@yeah.net · 0731-88618285
    • Peiguo Cao, Doctor · Principal investigator
  • Huaian First People's Hospital
    Huai'an, Jiangsu 223300, China
    Not yet recruiting
    • Changhua Yu, Master · Contact1131603215@qq.com
    • Changhua Yu, Master · Principal investigator
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu 210029, China
    Not yet recruiting
    • Jifeng Feng, Doctor · Contactfjif@vip.sina.com · 025-83283415
    • Jifeng Feng, Doctor · Principal investigator
  • Jiangsu People's Hospital
    Nanjing, Jiangsu 210029, China
    Not yet recruiting
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330012, China
    Not yet recruiting
    • Junhe Li, Doctor · Contactlijunhe88@163.com
    • Junhe Li, Doctor · Principal investigator
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
    Not yet recruiting
    • Yufeng Cheng, Doctor · Contactqlcyf@163.com · 0531-82169821
    • Yufeng Cheng, Doctor · Principal investigator
  • Baoji Central Hospital
    Baoji, Shanxi 721008, China
    Not yet recruiting
    • Yi Geng, Master · Contactgengyi0917@126.com · 0917-3390834
    • Yi Geng, Master · Principal investigator
    • Kai Chen, Master · Principal investigator
  • Shanxi Cancer Hospital
    Taiyuan, Shanxi 030000, China
    Not yet recruiting
    • Weihua Yang, Master · Contactywh1964@qq.com · 0351-4651623
    • Weihua Yang, Master · Principal investigator
  • Xijing Hospital of Airforce Medical University
    Xi'an, Shanxi 710000, China
    Not yet recruiting
  • First Affiliated Hospital of Xi'anjiantong University
    Xi'an, Shanxi 710061, China
    Recruiting
    • Xiaozhi Zhang, Doctor · Contactzhang9149@sina.com · 029-85324019
    • Xiaozhi Zhang, Doctor · Principal investigator
  • Tianjin Cancer Hospital
    Tianjin, Tianjin 300060, China
    Not yet recruiting
  • The first Hospital of Zhengjiang Province
    Hangzhou, Zhejiang 310000, China
    Not yet recruiting
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310005, China
    Recruiting
  • Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310006, China
    Not yet recruiting
    • Bing Xia, Doctor · Contactxb0918@hotmail.com · 0571-56006382
    • Bing Xia, Doctor · Principal investigator
  • Zhejiang Hospital
    Hangzhou, Zhejiang 310013, China
    Not yet recruiting
    • Zhibing Wu, Doctor · Contactwu_zhibing@163.com
    • Zhibing Wu, Doctor · Principal investigator
  • Zhejiang People's Hospital
    Hangzhou, Zhejiang 310014, China
    Not yet recruiting
    • Xiaodong Liang, Doctor · Contactlxdctopone@sina.com
    • Xiaodong Liang, Doctor · Principal investigator
  • Ningbo Medical Center Lihuili Hospital
    Ningbo, Zhejiang 315000, China
    Not yet recruiting
    • Hongcheng Wu, Master · Contactdoctorwu1967@126.com · 0574-87018581
    • Hongcheng Wu, Master · Principal investigator
  • Taizhou Hospital of Zhejiang Province
    Taizhou, Zhejiang 317000, China
    Not yet recruiting
  • Taizhou Central Hospital
    Taizhou, Zhejiang 318000, China
    Not yet recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2020 (actual). Primary completion is estimated for Dec 2022, 31 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 31 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2020
First posted
Mar 30, 2020
StartActual
May 27, 2020
Primary completionEst.
Dec 2022
CompletionEst.
Mar 2025
Last update
Mar 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04325763
Responsible party
Sponsor
First posted
Mar 30, 2020
Start date
May 27, 2020
Primary completion
Dec 2022 (estimated)
Completion
Mar 2025 (estimated)
Last update
Mar 31, 2022

Study contacts

Ming Chen
Contact
chenming@zjcc.org.cn
0571-88122508

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Benmelstobart · Anlotinib

Start the discussion